VERTEX PHARMACEUTICALS INC / MA - COM (VRTX)

Historical Portfolio Holders from Q1 2014 to Q3 2024

All holders as of September 30, 2024
Q3 2024
Type / Class
Equity / COM
Shares, excl. options Q3 2024
231M
Holdings value Q3 2024
$107B
Value change Q3 2024
-$1.71B
Grand Portfolio weight change Q3 2024
-0.003%
Number of holders
1489
Number of buys Q3 2024
700
Number of sells Q3 2024
-663
Average buys Q3 2024 %
+0.007%
Average sells Q3 2024 %
-0.008%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 231M $107B -$1.71B $465.08 1,498
2024 Q2 234M $110B +$1.77B $468.72 1,528
2024 Q1 230M $96.2B -$1.69B $418.01 1,462
2023 Q4 234M $95.2B +$938M $406.89 1,414
2023 Q3 231M $80.5B -$1.48B $347.74 1,258
2023 Q2 236M $82.9B -$316M $351.91 1,257
2023 Q1 236M $74.5B +$542M $315.07 1,177
2022 Q4 235M $67.9B -$1.29M $288.78 1,195
2022 Q3 235M $68.2B +$477M $289.54 1,103
2022 Q2 233M $65.8B +$694M $281.79 1,091
2022 Q1 233M $60.7B +$1.11B $260.97 1,047
2021 Q4 229M $50.2B -$246M $219.60 1,010
2021 Q3 230M $41.7B -$231M $181.39 918
2021 Q2 231M $46.6B -$421M $201.63 958
2021 Q1 235M $50.5B -$676M $214.89 977
2020 Q4 239M $56.4B -$910M $236.34 946
2020 Q3 242M $65.8B -$144M $272.12 928
2020 Q2 242M $70.3B -$450M $290.31 948
2020 Q1 244M $58.1B +$194M $237.95 845
2019 Q4 243M $53.3B -$519M $218.95 800
2019 Q3 246M $41.6B +$12.6M $169.42 698
2019 Q2 246M $45B +$694M $183.38 710
2019 Q1 245M $45.1B +$342M $183.95 731
2018 Q4 243M $40.3B +$326M $165.71 692
2018 Q3 241M $46.5B +$73.1M $192.74 690
2018 Q2 241M $41B +$46.8M $169.96 684
2018 Q1 241M $39.2B +$165M $162.98 680
2017 Q4 240M $35.9B +$290M $149.86 640
2017 Q3 238M $36.1B +$312M $152.04 602
2017 Q2 236M $30.4B +$56.1M $128.87 574
2017 Q1 236M $25.8B +$2.17B $109.35 509
2016 Q4 236M $17.4B -$357M $73.67 471
2016 Q3 241M $21B +$86.9M $87.21 479
2016 Q2 240M $20.6B +$257M $86.02 473
2016 Q1 234M $18.6B -$154M $79.49 485
2015 Q4 234M $29.5B +$21.1M $125.83 510
2015 Q3 231M $24.1B +$716M $104.14 485
2015 Q2 230M $28.4B -$404M $123.48 494
2015 Q1 233M $27.5B +$443M $117.97 471
2014 Q4 230M $27.3B -$490M $118.80 466
2014 Q3 233M $26.2B +$764M $112.31 422
2014 Q2 227M $21.5B +$278M $94.68 406
2014 Q1 223M $15.8B +$103M $70.72 390